Erasca, Inc.
ERAS
Rank in Stocks
#3619
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Share Price
$13.45
Last synced: 2026-10-16
Market Cap
$4.70B
Change (1 day)
-9.58%
Change (1 year)
455.58%
Country
US
Trade Erasca, Inc. (ERAS)
Category
Healthcare
EPS for Erasca, Inc. (ERAS)
EPS as of June 2026 TTM: $-0.95
According to Erasca, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-0.95. At the end of 2023 the company had a EPS of $-0.83 a decrease compared to its 2022 EPS that were of $-1.99.
EPS history for Erasca, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.95 | 37.68% |
| 2024 | $-0.69 | -16.87% |
| 2023 | $-0.83 | -58.29% |
| 2022 | $-1.99 | 93.20% |
| 2021 | $-1.03 | 21.18% |
| 2020 | $-0.85 | 750.00% |
| 2019 | $-0.10 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -1,923.16% |
US
|
|
| $-7.98 | 740.00% |
US
|
|
| $-5.29 | 456.84% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,020.00% |
NL
|
